Cardiorenal syndrome: the role of new biochemical markers

Salvatore Novo, Filippo Ferrara, Federica Vernuccio, Giuseppina Novo, Federica Vernuccio, Giuseppe Grutta, Salvatore Novo, Giuseppina Novo, Filippo Ferrara, Giovanni Fazio

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cardiorenal syndrome is a pathophysiological heart and kidney disorder, in which acute or chronic dysfunction of one organ induces a damage in the other. It's a syndrome more and more often encountered in clinical practice and this implies the need to recognize the syndrome through biochemical markers with a good sensitivity and specificity, since its earliest stages in order to optimize therapy. In addition to widely validated biomarkers, such as BNP, pro BNP, creatinine, GFR and cystatin C, other promising molecules are available, like NGAL (neutrophil gelatinase-associated lipocalin, KIM-1 (kidney injury molecule-1), MCP-1 (monocyte chemotactic peptide), Netrin-1, interleuchin 18 and NAG (N-acetyl-β-glucosa-minidase). The role of these emerging biomarkers is still not completely clarified: hence the need of new clinical trials.
Original languageItalian
Pages (from-to)559-563
Number of pages5
JournalRECENTI PROGRESSI IN MEDICINA
Volume103
Publication statusPublished - 2012

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Novo, S., Ferrara, F., Vernuccio, F., Novo, G., Vernuccio, F., Grutta, G., Novo, S., Novo, G., Ferrara, F., & Fazio, G. (2012). Cardiorenal syndrome: the role of new biochemical markers. RECENTI PROGRESSI IN MEDICINA, 103, 559-563.